<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02342366</url>
  </required_header>
  <id_info>
    <org_study_id>PUK-GHB01</org_study_id>
    <nct_id>NCT02342366</nct_id>
  </id_info>
  <brief_title>Characterization of the Prosocial and Prosexual Effects of GHB</brief_title>
  <official_title>Multimodal Characterization of the Prosocial and Prosexual Effects of GHB Assessing Behavior, fMRI, EEG, and Neuroendocrine Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Salerno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether gamma-Hydroxybutyrate (GHB) has prosocial
      and prosexual effects in healthy male participants, and to characterize these putative
      effects via behavioral tests, functional magnetic resonance imaging (fMRI),
      electroencephalography (EEG), and neuroendocrine parameters. The investigators predict that
      GHB in fact has prosocial and prosexual effects which can be neurobiologically characterized
      using the assessed methods. Such effects would be of high interest for the treatment of
      mental disorders which involve impairments of social interaction and sexual function such as
      major depression or autism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction

      Gammahydroxybutyrate (GHB) is an endogenous short-chain fatty acid and discussed as a
      neurotransmitter (Bessman and Fishbein, 1963) with high affinity to specific GHB (Benavides
      et al., 1982; Snead, 2000) and α4βδ-gamma-Aminobutyric acid (GABA)A receptors (Absalom et
      al., 2012) that also binds with lower affinity to GABAB receptors (Engberg and Nissbrandt,
      1993). It is internationally used as standard treatment for narcolepsy with cataplexy
      (Alshaikh et al., 2012), and in some European countries for alcohol withdrawal and craving
      (Keating, 2014). Additionally, recent randomized controlled studies showed therapeutic
      effects in fibromyalgia (Spaeth et al., 2013). Anecdotal reports from GHB abusers indicate
      mood enhancing, prosocial and prosexual effects of the drug (Sumnall et al., 2008), which
      were not objectively assessed so far. Impaired social decision making is a behavioral finding
      in depression (Pulcu et al., 2014), that is related to social withdrawal symptoms. Moreover,
      sexual dysfunction is both a symptom of depression and an adverse effect of most
      antidepressant medications (Kennedy and Rizvi, 2009), with a deteriorating impact on quality
      of life measures. Due to its unique pharmacologic effects on sleep, daytime vigilance, pain,
      and social interaction, GHB was recently proposed as experimental therapeutic for the
      treatment of depression (Bosch et al., 2012).

      Study Aims

      A) Investigating the putative prosocial effects of GHB in humans B) Investigating the
      putative prosexual effects of GHB in humans C) Investigating the neuroendocrine mechanisms of
      putative prosocial and prosexual effects of GHB in humans D) Investigating
      electrophysiological effects of GHB in decision-making in humans E) Investigating the
      functional neurobiology of GHB and its putative prosexual effects in humans

      Study Design

      A) The effects of GHB on social cognition, sexual arousal, neuroendocrine parameters, and EEG
      measures in healthy subjects: GHB (20 mg/kg p.o.) was tested in 16 healthy males, using a
      randomized, placebo-controlled, cross-over design. Subjective effects on mood were assessed
      by visual analogue scales (VAS) and the GHB Specific Questionnaire (GSQ). Prosocial behavior
      was examined by the Charity Donation Task, the Social Value Orientation test, and the
      Reciprocity Task. We assessed reaction time and motor performance using the Delayed Matching
      to Sample and the Reaction Time tasks from the Cambridge Neuropsychological Test Automated
      Battery (CANTAB). We assessed social cognition using the Multifaceted Empathy Task (MET) and
      the Movie for the Assessment of Social Cognition (MASC). We assessed memory using a German
      version of the Rey Auditory Verbal Learing Task. Sexual arousal was assessed using the Sexual
      Arousal and Desire Inventory (SADI), sexual perception was assessed using a self-designed
      Sexual Arousal Task (SAT). Furthermore, the investigators assessed GHB effects on brain
      electrophysiological activity using electroencephalography (EEG) and a flanker task for the
      assessment of error-related negativity. Blood plasma levels of GHB, oxytocin, testosterone,
      progesterone, dehydroepiandrosterone (DHEA), cortisol, aldosterone, and adrenocorticotropic
      hormone (ACTH) were determined.

      B) The effects of GHB on neuronal networks and sexual arousal in healthy subjects - an fMRI
      study: The investigators performed a characterization of the putative prosexual effects of
      GHB (35 mg/kg vs. placebo p.o.) in 19 healthy participants. Questionnaires (VAS, SADI, GSQ)
      were used to assess subjective aspects. Brain reactivity towards erotic vs. neutral pictures
      of persons, as well as resting state connectivity and arterial spin labelling (ASL) was
      investigated with functional magnetic resonance imaging (fMRI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sexual Arousal</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in sexual arousal after GHB challenge compared to placebo (Sexual Arousal and Desire Inventory [SADI], Sexual Arousal Task [SAT], brain reactivity towards erotic vs. neutral pictures ([fMRI-Task])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Social Cognition and Behavior</measure>
    <time_frame>14 days</time_frame>
    <description>Changes in social cognition and behavior after GHB challenge compared to placebo (Charity Donation Task, Social Value Orientation test, Reciprocity Task, Multifaceted Empathy Task [MET], Movie for the Assessment of Social Cognition [MASC])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite measure of Neuroendocrine Parameters</measure>
    <time_frame>14 days</time_frame>
    <description>Testosterone, DHEA, cortisol, aldosterone, ACTH, progesterone, oxytocin plasma levels after GHB challenge compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electroencephalography (EEG) activity</measure>
    <time_frame>14 days</time_frame>
    <description>EEG activity during a flanker task after GHB challenge compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI activity</measure>
    <time_frame>14 days</time_frame>
    <description>Brain activity in fMRI after GHB challenge compared to placebo (Picture-Task, Resting State Connectivity, ASL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Autistic Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GHB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GHB 35 mg/kg p.o.</intervention_name>
    <description>GHB 35 mg/kg p.o.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>GHB</arm_group_label>
    <other_name>Sodium Oxybate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GHB 20 mg/kg p.o.</intervention_name>
    <description>GHB 20 mg/kg p.o.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>GHB</arm_group_label>
    <other_name>Sodium Oxybate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects.

        Exclusion Criteria:

          -  Any Axis-I DSM-IV psychiatric disorder, any form of addiction or regular illegal drug
             use (lifetime use &gt;5 occasions) with exception of occasional cannabis use, a lifetime
             history of GHB use, a neurological disorder or head injury, clinically relevant
             medical diseases, a family history of schizophrenia or bipolar disorder, and any use
             of prescription drugs.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erich Seifritz, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Psychiatry, University of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Absalom N, Eghorn LF, Villumsen IS, Karim N, Bay T, Olsen JV, Knudsen GM, Bräuner-Osborne H, Frølund B, Clausen RP, Chebib M, Wellendorph P. α4βδ GABA(A) receptors are high-affinity targets for γ-hydroxybutyric acid (GHB). Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13404-9. doi: 10.1073/pnas.1204376109. Epub 2012 Jul 2.</citation>
    <PMID>22753476</PMID>
  </reference>
  <reference>
    <citation>Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012 Aug 15;8(4):451-8. doi: 10.5664/jcsm.2048. Review.</citation>
    <PMID>22893778</PMID>
  </reference>
  <reference>
    <citation>Benavides J, Rumigny JF, Bourguignon JJ, Cash C, Wermuth CG, Mandel P, Vincendon G, Maitre M. High affinity binding sites for gamma-hydroxybutyric acid in rat brain. Life Sci. 1982 Mar 15;30(11):953-61.</citation>
    <PMID>7070203</PMID>
  </reference>
  <reference>
    <citation>BESSMAN SP, FISHBEIN WN. GAMMA-HYDROXYBUTYRATE, A NORMAL BRAIN METABOLITE. Nature. 1963 Dec 21;200:1207-8.</citation>
    <PMID>14089913</PMID>
  </reference>
  <reference>
    <citation>Bosch OG, Quednow BB, Seifritz E, Wetter TC. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol. 2012 May;26(5):618-28. doi: 10.1177/0269881111421975. Epub 2011 Sep 17. Review.</citation>
    <PMID>21926421</PMID>
  </reference>
  <reference>
    <citation>Engberg G, Nissbrandt H. gamma-Hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABAB-receptors. Naunyn Schmiedebergs Arch Pharmacol. 1993 Nov;348(5):491-7.</citation>
    <PMID>8114948</PMID>
  </reference>
  <reference>
    <citation>Keating GM. Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clin Drug Investig. 2014 Jan;34(1):63-80. doi: 10.1007/s40261-013-0158-x. Review.</citation>
    <PMID>24307430</PMID>
  </reference>
  <reference>
    <citation>Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009 Apr;29(2):157-64. doi: 10.1097/JCP.0b013e31819c76e9. Review.</citation>
    <PMID>19512977</PMID>
  </reference>
  <reference>
    <citation>Pulcu E, Thomas EJ, Trotter PD, McFarquhar M, Juhasz G, Sahakian BJ, Deakin JF, Anderson IM, Zahn R, Elliott R. Social-economical decision making in current and remitted major depression. Psychol Med. 2015 Apr;45(6):1301-13. doi: 10.1017/S0033291714002414. Epub 2014 Oct 10.</citation>
    <PMID>25300570</PMID>
  </reference>
  <reference>
    <citation>Snead OC 3rd. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem. 2000 Nov;75(5):1986-96.</citation>
    <PMID>11032888</PMID>
  </reference>
  <reference>
    <citation>Spaeth M, Alegre C, Perrot S, Wang Y, Guinta DR, Alvarez-Horine S, Russell I; Sodium Oxybate Fibromyalgia Study Group. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia. Arthritis Res Ther. 2013 Nov 11;15(6):R185. doi: 10.1186/ar4375.</citation>
    <PMID>24286114</PMID>
  </reference>
  <reference>
    <citation>Sumnall HR, Woolfall K, Edwards S, Cole JC, Beynon CM. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008 Jan 1;92(1-3):286-90. Epub 2007 Sep 4.</citation>
    <PMID>17766059</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sodium Oxybate, Altruism, Neurostreroids, Liquid Ecstasy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

